Alexion Pharma (ALXN) Tops Q2 EPS by 30c, Sales Beat; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharmaceuticals (ALXN) PT Raised to $168 at BMO Capital on 2Q Beat; 'Upside in Soliris Sales, Upward Revision to Sales Guidance'
July 28, 2017 10:31 AM EDTBMO Capital raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $168.00 (from $159.00) while maintaining a Outperform rating, following the company's second quarter earnings report.
Analyst M. Ian Somaiya notes a positive outlook, as the company delivered second quarter earnings per share and... More
Alexion Pharmaceuticals (ALXN) PT Raised to $170 at Leerink Partners
July 28, 2017 10:20 AM EDTLeerink Partners raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $170.00 (from $136.00) while maintaining a Outperform rating. ALXN reported Q2 results and delivered a solid revenue and EPS beat vs. consensus. Management highlighted that the biggest contributors to the revenue growth were strong volume... More
